Pollak Catherine, Parambath Andrew, Coratti Samantha, Norton Laurie, Girard Anthony, Reitz Catherine, Snider Christopher K, Xu Lin, Walker Zakiya, John Aileen, Putt Mary E, Volpp Kevin G, Mehta Shivan J
Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia.
Grossman School of Medicine, New York University, New York.
JAMA Cardiol. 2025 Apr 1;10(4):313-320. doi: 10.1001/jamacardio.2024.5281.
A comprehensive lipid panel is recommended by guidelines to evaluate atherosclerotic cardiovascular disease risk, but uptake is low.
To evaluate whether direct outreach including bulk orders with and without text messaging increases lipid screening rates.
DESIGN, SETTING, AND PARTICIPANTS: Pragmatic randomized clinical trial conducted from June 6, 2023, to September 6, 2023, at 2 primary care practices at an academic health system among patients aged 20 to 75 years with at least 1 primary care visit in the past 3 years who were overdue for lipid screening. Data analysis was performed from September 2023 to May 2024.
Eligible patients were randomized in a 1:2:2 ratio to usual care (group 1), direct outreach and bulk orders (group 2), and bulk order outreach with additional text message reminders for scheduling assistance (group 3). In group 3, participants received an initial, follow-up, and reminder text message. Patients with electronic portal accounts were encouraged to schedule through them, while others received laboratory contact information. Any participant inquiries were answered either with automated responses for common questions or with study team support.
Proportion of patients who completed a lipid panel within 3 months.
Among the 1000 participants, the median (IQR) age was 38 (28-55) years; 470 (47.0%) were female; and 22 (2.3%) were Asian, 38 (3.9%) were Black, 32 (3.2%) were Hispanic or Latino, and 862 (88.6%) were White (race and ethnicity were based on self-reported data). At 3 months, a lipid panel was completed by 12 of 202 patients (5.9%; 95% CI, 3.4% to 10.1%) receiving usual care (group 1) vs 62 of 394 patients (15.7%; 95% CI, 12.5% to 19.7%) receiving direct outreach and bulk order (group 2), a difference of 9.8 percentage points (95% CI, 4.6 to 15.0; P = .001). The panel was completed by 73 of 404 patients (18.1%; 95% CI, 14.6% to 22.1%) receiving outreach, bulk order, and text message reminders (group 3), for a difference of 2.4 percentage points (95% CI, -3.1 to 7.8; P = .43) vs outreach with bulk order alone (group 2). At 6 months, there were no significant differences in lipid screening between either group 1 vs group 2 or group 2 vs group 3.
Lipid screening among participants receiving bulk orders and outreach letters increased significantly compared with usual care at 3 months. However, there was no difference at 6 months. More than 80% of patients did not follow through with lipid screening despite the intervention, and there was no additional increase in lipid testing at 3 months among participants receiving bulk ordering and supplemental text messaging.
ClinicalTrials.gov Identifier: NCT05724615.
指南推荐通过全面血脂检测来评估动脉粥样硬化性心血管疾病风险,但检测率较低。
评估直接推广(包括批量订购以及有无短信提醒)是否能提高血脂筛查率。
设计、地点和参与者:2023年6月6日至2023年9月6日在一个学术健康系统的2家基层医疗诊所进行的实用随机临床试验,参与者为年龄在20至75岁之间、过去3年至少有1次基层医疗就诊且血脂筛查逾期的患者。数据分析于2023年9月至2024年5月进行。
符合条件的患者按1:2:2的比例随机分为常规护理组(第1组)、直接推广和批量订购组(第2组)以及批量订购推广并额外发送短信提醒以协助安排检测组(第3组)。在第3组中,参与者收到初始、跟进和提醒短信。鼓励有电子门户账户的患者通过该账户安排检测,其他患者则收到实验室联系信息。对参与者的任何询问,要么通过对常见问题的自动回复,要么通过研究团队支持进行解答。
在3个月内完成血脂检测的患者比例。
1000名参与者中,年龄中位数(四分位间距)为38(28 - 55)岁;470名(47.0%)为女性;22名(2.3%)为亚洲人,38名(3.9%)为黑人,32名(3.2%)为西班牙裔或拉丁裔,862名(88.6%)为白人(种族和族裔基于自我报告数据)。3个月时,接受常规护理的202名患者中有12名(5.9%;95%置信区间,3.4%至10.1%)完成了血脂检测(第1组),而接受直接推广和批量订购的394名患者中有62名(15.7%;95%置信区间,12.5%至19.7%)完成了检测(第2组),差异为9.8个百分点(95%置信区间,4.6至15.0;P = 0.001)。接受推广、批量订购和短信提醒的404名患者中有73名(18.1%;95%置信区间,14.6%至22.1%)完成了检测(第3组),与仅接受批量订购推广(第2组)相比,差异为2.4个百分点(95%置信区间,-3.1至7.8;P = 0.43)。6个月时,第1组与第2组或第2组与第3组之间的血脂筛查无显著差异。
与常规护理相比,接受批量订购和推广信的参与者在3个月时血脂筛查显著增加。然而,6个月时无差异。尽管进行了干预,但超过80%的患者未进行血脂筛查,并且在接受批量订购和补充短信的参与者中,3个月时血脂检测没有额外增加。
ClinicalTrials.gov标识符:NCT05724615。